Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 6/20 | 0.68 |
| ▸ | HTR1D | P28221 | 5/20 | 0.68 |
| ▸ | ADRA2B | P18089 | 5/20 | 0.62 |
| ▸ | ADRA2C | P18825 | 5/20 | 0.62 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.62 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.62 |
| ▸ | HTR1A | P08908 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.62 |
| ▸ | HTR1B | P28222 | 4/20 | 0.61 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.61 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10142828 | 0.85 | NISCH (0.60) | TAAR1HTR1DADRA2BADRA2CADRA2A | |
| Nemazoline SCHEMBL4630344 | 0.83 | HTR1B (0.49) | TAAR1HTR1DADRA2BADRA2CADRA2A | |
| SCHEMBL954681 | 0.83 | TAAR1 (0.73) | TAAR1HTR1DADRA2BADRA2CADRA2A | |
| SCHEMBL953521 | 0.81 | HTR1D (1.00) | TAAR1HTR1DADRA2BADRA2CADRA2A | |
| SCHEMBL954604 | 0.80 | HTR1D (0.60) | TAAR1HTR1DADRA2BADRA2CADRA2A | |
| SCHEMBL953637 | 0.80 | TAAR1 (0.83) | TAAR1HTR1DADRA2BADRA2CADRA2A | |
| SCHEMBL954827 | 0.79 | TAAR1 (0.68) | TAAR1HTR1DADRA2BADRA2CADRA2A | |
| SCHEMBL953100 | 0.79 | TAAR1 (0.62) | TAAR1HTR1DADRA2BADRA2CADRA2A | |
| SCHEMBL26078623 | 0.79 | NISCH (0.58) | TAAR1HTR1DADRA2BADRA2CADRA2A | |
| SCHEMBL26078478 | 0.79 | NISCH (0.59) | TAAR1HTR1DADRA2BADRA2CADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101374516-A | Use of substituted 2-imidazole of imidazoline derivatives | HOFFMANN LA ROCHE (CH) | 2009-02-25 | — | — | CN | claimed |
| EP-1981497-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-22 | — | — | EP | claimed |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | claimed |
| WO-2007085557-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | WO | claimed |
| US-20230312524-A1 | ALPHA1A-ADRENERGIC RECEPTOR AGONISTS AND METHODS OF USE | CURASEN THERAPEUTICS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-7875645-B2 | 2-(2-cyclopropyl-benzyl)-4,5-dihydro-1H-imidazole; depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders | HOFFMAN-LA ROCHE INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-7875645-B2 | 2-(2-cyclopropyl-benzyl)-4,5-dihydro-1H-imidazole; depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders | HOFFMAN-LA ROCHE INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-7875645-B2 | 2-(2-cyclopropyl-benzyl)-4,5-dihydro-1H-imidazole; depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders | HOFFMAN-LA ROCHE INC. (US) | 2011-01-25 | — | — | US | disclosed |
| CN-101374516-A | Use of substituted 2-imidazole of imidazoline derivatives | HOFFMANN LA ROCHE (CH) | 2009-02-25 | — | — | CN | disclosed |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| WO-2007085557-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | GPR119, PER2, MTNR1B | TAAR1 117/4885HTR1D 28/4885ADRA2B 77/4885 |
| US-20230312524-A1 | ALPHA1A-ADRENERGIC RECEPTOR AGONISTS AND METHODS OF USE | ADRA1A, ADRB1, ADRA1D | TAAR1 26/4885HTR1D 47/4885ADRA2B 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.